Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim

Wearable Technology to Evaluate Hyperglycemia and Heart Rate Variability in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death. Heart failure is a leading cause of death in DMD, but substantial knowledge gaps exist regarding predisposing risk factors. In the general population, hyperglycemia, insulin resistance, and decreased heart rate variability (HRV; reflecting autonomic dysfunction) are associated with cardiomyopathy (CM). It is unclear whether these factors are associated with DMD-CM. Closing this knowledge gap may lead to novel screening and therapeutic strategies to delay progression of DMD related CM. Despite risk factors for hyperglycemia, including the use of glucocorticoids, low muscle mass, obesity, and reduced ambulation, little is known regarding glucose abnormalities in DMD. Some of these same risk factors, along with the distance needed to travel for specialty care, present significant barriers to research participation and clinical care for individuals with DMD. Remote wearable technology may improve research participation in this vulnerable population. Therefore, this study will leverage remote wearable technologies to overcome these barriers and define the relationship between dysglycemia and DMD-CM.

In this Aim of the study, the investigators will assess the utility of remote wearable technology to predict changes in traditional metrics of metabolism and cardiac function. In this pilot study, 10 individuals with DMD will undergo cardiac magnetic resonance imaging (CMR) and oral glucose tolerance tests (OGTTs) at baseline and two years. The investigators will remotely assess glycemia (using continuous glucose monitors), HRV (using extended Holter monitors), and activity (using accelerometers) every 6 months over the 2 years and evaluate if changes in wearable metrics predict changes in CMR and OGTT.

Study Overview

• Status: Recruiting
• Conditions: Duchenne Muscular Dystrophy
• Intervention / Treatment: Device: wearable technology

Detailed Description

Risk for hyperglycemia and insulin resistance in DMD: Individuals with DMD have multiple risk factors for abnormal glucose and insulin metabolism: frequent use of glucocorticoid (GC) medication, decreased ambulation/activity, sarcopenia, and obesity. GC use is known to increase the risk of impaired glucose tolerance (IGT) and insulin resistance (IR) in multiple populations. Decreased skeletal muscle mass and function are associated with impaired skeletal muscle insulin sensitivity and type 2 diabetes (T2D). Despite these risks, there are limited data relating glycemia and IR in this population.

This study is a critical first step in evaluating hyperglycemia in DMD and the relationship to autonomic dysfunction. Our findings will help establish screening guidelines and provide a basis for intervention studies targeting glycemia in DMD. Additionally, this study, along with other ongoing studies (Remote study: Wearable Technology to Evaluate Hyperglycemia and Heart Rate Variability in Duchenne Muscular Dystrophy) will establish wearable technology as investigational tools, for potential use in future clinical trials, in individuals with DMD and neuromuscular diseases.

Study Population: This study will include approximately 10 male participants at Vanderbilt with DMD.

DMD is an X-linked disorder affecting approximately 1/3500-6000 males and 1/50 million females. Therefore, only males will be included in this study.

Study Enrollment Period: Expected duration of the study is 6 years.

Study Visits and procedures:

Visit 1 (V1): in-person study visit

• Participants will arrive to the research clinic after an overnight fast
• Visit includes medical history, physical exam, a fasting oral glucose tolerance test (OGTT), blood will be drawn, dual-energy X-ray absorptiometry (DXA) scan, and cardiac MRI (CMR).
• Participants will wear remote monitoring devices including a continuous glucose monitor (CGM) for up to 10 days, an activity monitor (Actigraph) for up to 7 days, and a Holter (cardiac) monitor for up to 7 days.
• Participants will complete a brief diary/survey twice daily during the 7 days they are wearing the ActiGraph, Holter, and CGM. This survey will be texted or emailed to participants in the morning and evening and take approximately 5 minutes to complete. The questions are primarily related to sleep, activity, and food intake

Visit 2 (V2): remote, 6 months after Visit 1

• Participants will wear remote monitoring devices including a continuous glucose monitor (CGM) for up to 10 days, an activity monitor (Actigraph) for up to 7 days, and a Holter (cardiac) monitor for up to 7 days.
• Repeat the brief diary/survey as V1.

Visit 3 (V3): remote, 12 months after Visit 1

• Same study procedures as V2.

Visit 4 (V4): remote, 18 months after Visit 1

• Same study procedures as V2.

Visit 5 (V5): in-person study visit, approximately 24 months after Visit 1 • Same study procedures as V1.

*If the participant has completed a cardiac MRI or other study procedure for an alternate clinical or research evaluation within a month of other study procedures, the investigators may be able to use that data instead of repeating the study procedure.

• Study Type: Observational
• Enrollment (Estimated): 10

Contacts and Locations

• Study Contact: Name: Wendi Welch; Phone Number: 615-875-9233; Email: wendi.m.welch@vumc.org
• Study Contact Backup: Name: Jaclyn Tamaroff, MD; Phone Number: 615-875-7853; Email: Jaclyn.tamaroff@vumc.org

Study Locations

• United States
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Recruiting
      • Vanderbilt University Medical Center
      • Contact: Wendi Welch; Phone Number: 615-875-9233; Email: wendi.m.welch@vumc.org
      • Contact: Jaclyn Tamaroff, MD; Phone Number: 615-875-7853; Email: Jaclyn.tamaroff@vumc.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

10 adolescent and young adult males with DMD. DMD affects about 1/3500-6000 males and 1/50million females, therefore only male participants will be enrolled.

Description

Inclusion and Exclusion Criteria:

Inclusion criteria

• Male- ≥10 years
• Clinical phenotype of DMD confirmed with muscle biopsy or genotype.
• Informed consent for individuals ≥18 years
• Parent/guardian informed consent and child assent for individuals < 18 years
• Able to undergo non-sedated CMR

Exclusion Criteria

• Refusal to participate
• Diagnosis of diabetes prior to the study and/or taking insulin or other anti-diabetic drug therapy in < 4 weeks prior to treatment
• Inability to fast for 10 hours
• Use of a pacemaker, implantable cardioverter-defibrillator (ICD), or other implanted device
• Unable to comply with study procedures, in the opinion of the investigator.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of hyperglycemia	number of glucose measurements ≥140mg/dL over total number of glucoses	5 time points, each over 10 days
Standard deviation of the mean R-to-R segment (SDANN)	correlation of rate of hyperglycemia and SDANN, which reflects heart rate variability	5 time points, each over 7 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Coefficient of variation on CGM	variability of glucose levels on CGM measured by coefficient of variation (COV)	5 time points, each over 10 days
Rate of significant hyperglycemia	number of glucose measurements ≥200mg/dL over total number of glucoses	5 time points, each over 10 days
Activity level	Time spent in sedentary, low intensity, and moderate to vigorous physical activity	5 time points, each over 7 days
Standard deviation of normal R to R intervals (SDNN)	correlation of rate of hyperglycemia and SDNN	5 time points, each over 7 days
Late gadolinium enhancement (LGE)	correlation of change in SDANN from 0 to 24 months with change in percent LVEF on cardiac MRI from 0 to 24 months	2 time points: initially and approximately 2 years later
Left ventricular ejection fraction (LVEF)	correlation of change in SDANN from 0 to 24 months with change in percent LVEF on cardiac MRI from 0 to 24 months	2 time points: initially and approximately 2 years later
Insulin sensitivity	correlation between change in rate of hyperglycemia from 0 to 24 months (CGM) with change in insulin sensitivity from 0 to 24 months (oral glucose tolerance test)	2 time points: initially and approximately 2 years later

Collaborators and Investigators

• Sponsor: Vanderbilt University Medical Center
• Investigators: Principal Investigator: Jaclyn Tamaroff, MD, Vanderbilt University Medical Center

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2024
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): December 1, 2030

Study Registration Dates

• First Submitted: October 10, 2023
• First Submitted That Met QC Criteria: October 16, 2023
• First Posted (Actual): October 23, 2023

Study Record Updates

• Last Update Posted (Actual): April 17, 2024
• Last Update Submitted That Met QC Criteria: April 15, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: heart failure; Duchenne Muscular Dystrophy; hyperglycemia; heart rate variability; cardiomyopathy
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Diseases; Muscular Disorders, Atrophic; Hyperglycemia; Muscular Dystrophies; Muscular Dystrophy, Duchenne
• Other Study ID Numbers: 231407

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes